| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 6.749 | 8.016 | 7.881 | 7.736 | 7.586 | 7.442 | 7.277 | 7.300 | 7.278 | 7.237 |
| Total Income - EUR | 6.749 | 8.016 | 7.881 | 8.639 | 8.634 | 7.442 | 15.363 | 10.342 | 7.278 | 7.237 |
| Total Expenses - EUR | 13.785 | 13.621 | 13.258 | 17.534 | 12.869 | 16.754 | 14.439 | 9.390 | 8.031 | 7.257 |
| Gross Profit/Loss - EUR | -7.036 | -5.605 | -5.378 | -8.895 | -4.235 | -9.311 | 925 | 952 | -753 | -20 |
| Net Profit/Loss - EUR | -7.238 | -5.725 | -5.456 | -8.972 | -4.310 | -9.518 | 464 | 648 | -753 | -20 |
| Employees | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Gabformin S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 115.846 | 111.418 | 106.087 | 98.252 | 94.692 | 80.884 | 73.057 | 70.897 | 68.302 | 65.592 |
| Current Assets | 23.040 | 25.096 | 24.661 | 23.864 | 23.179 | 17.090 | 11.808 | 18.101 | 18.003 | 20.430 |
| Inventories | 2.392 | 2.368 | 2.328 | 2.282 | 2.238 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 20.092 | 22.007 | 21.854 | 21.204 | 19.926 | 16.202 | 11.232 | 17.966 | 17.483 | 20.347 |
| Cash | 556 | 721 | 480 | 378 | 1.015 | 889 | 576 | 135 | 520 | 83 |
| Shareholders Funds | 69.732 | 63.296 | 56.769 | 46.755 | 41.539 | 31.233 | 31.004 | 31.749 | 30.899 | 30.707 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 69.153 | 73.219 | 73.980 | 75.362 | 76.332 | 66.741 | 53.860 | 57.249 | 55.406 | 55.316 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "220 - 220" | |||||||||
| CAEN Financial Year |
220
|
|||||||||
Comments - Gabformin S.r.l.